# Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma

> **NCT05381506** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 77 (estimated)

## Conditions studied

- DLBCL

## Interventions

- **DRUG:** Orelabrutinib and Gemox

## Key facts

- **NCT ID:** NCT05381506
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07
- **Primary completion:** 2023-12
- **Final completion:** 2025-12
- **Target enrollment:** 77 (ESTIMATED)
- **Last updated:** 2022-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05381506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05381506, "Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05381506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*